Dolutegravir in Breast Milk and Maternal and Infant Plasma During Breastfeeding.

The integrase inhibitor dolutegravir (DTG) is a new effective first-line antiretroviral agent for treatment-naive HIV-positive individuals with a variety of baseline characteristics [1–5]. Because of its effectiveness, good tolerability, limited drug–drug interactions, and highresistance barrier, DTG is also suggested as possible treatment option in the resource-limited setting [6], where WHO recommends exclusive breastfeeding for infants of HIV-positive mothers, as formula feeding is associated with high infant mortality [7]. However, to date, no pharmacokinetic and safety data of DTG from lactating women and their breastfed infants are available. Here, we present the first case of DTG transfer into breast milk and the breastfed infant.